Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Investor Relations
Corporate Profile
Welcome to Taro’s Investor Relations Website
Established in 1950, Taro Pharmaceutical Industries Ltd. is a multinational science-based pharmaceutical company that develops, manufactures and markets generic and branded prescription and over-the-counter (OTC) pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve leadership in dermatological products in the United States.

Business Overview
Taro develops, manufactures and markets prescription and OTC pharmaceutical products primarily in the United States, Canada and Israel. Taro’s primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly for the dermatological, topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.

Webcast ImageTaro 2017/18 Year End Results Earnings Call
Friday, May 18, 2018, 8:00 AM EDT
Please click here to access the webcast
TARO (Common Stock)
ExchangeNYSE Arca (US Dollar)
Change (%) Stock is Down 0.67 (0.56%)
Data as of 06/19/18 3:42 p.m. ET
Click Here for Stock Quote Data on NYSE
Recent NewsMore >>
05/17/18Taro Provides Results for Year Ended March 31, 2018Printer Friendly Version
05/11/18Taro to Announce Full Year Results on May 17, 2018Printer Friendly Version
02/07/18Taro Provides Results for December 31, 2017Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Terms of Use
Privacy Statement
Safe Harbor Statement